Search

everythinglearnresearchcommunity

for

Search:↓

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Derinat may improve hair growth and quality of life in hair loss patients by reducing oxidative stress.

Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Tofacitinib taken by mouth helps treat hair loss in children.

Targeting ATM could help manage heart cell enlargement due to pressure overload.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.